Ponatinib Hydrochloride
|
|
Ponatinib Hydrochloride 속성
- 저장 조건
- -20°C
- 용해도
- DMF: 2 mg/ml,DMSO: 11 mg/ml,Ethanol: Slightly soluble
- 물리적 상태
- 고체
안전
- 위험 및 안전 성명
- 위험 및 사전주의 사항 (GHS)
Ponatinib Hydrochloride C화학적 특성, 용도, 생산
개요
In December 2012, the US FDA approved ponatinib (also referred to as AP 24534) for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronicmyeloid leukemia (CML). Ponatinib is a pan-Bcr–Abl TKI that blocks both the native (IC50=0.4 nM) and Bcr– AblT315I mutated kinases (IC50=2.0 nM) in addition to othermutated kinases in CML patients. In the Ba/F3 cell proliferation assay, ponatinib inhibits ABL and the T315I Abl mutant with IC50s of 1.2 and 8.8 nM, respectively. Ponatinib was identified by a structure-based drug design approach. Ponatinib binds to the kinase domain in a DFG-out conformation; the ethynyl moiety helps the inhibitor evade the mutant gatekeeper isoleucine residue at position 315. In addition to Abl and the T315I mutant of Abl, ponatinib inhibits VEGFR, PDGFR, FGFR, SRC, KIT, RET, TIE2, FLT3, and EPH receptors at concentrations ranging from0.1 to 20 nM.용도
Ponatinib is a tyrosine kinase inhibitors (TKI) and used to treat chronic myeloid leukemia (CML) (1,2,3). Ponatinib is also used in combination with other drugs, such as forskolin, to combat TKI resistance in patient with CML (3), targeted drug in small-cell lung cancer. Potent FAK inhibitor. FGFR/VEGFR/Bcr-Abl inhibitor It is a COVID19-related research product.Clinical Use
Ponatinib hydrochloride (Iclusig ®), previously known as AP24534, is a multi-targeted tyrosine kinase inhibitor approved in the US as an oral treatment for resistant or intolerant chronic myeloid leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). Ponatinib hydrochloride was designed for treatment of tumors containing the T351I mutation which are present in some forms of CML and resistant to traditional therapies such as imatinib. Ponatinib hydrochloride was developed by Ariad Pharmaceauticals, and operates by a similar mechanism of action as other tyrosine kinase inhibitors, inhibiting the enzymatic activity of BCR-ABL, an abnormal tyrosine kinase responsible for unregulated and excess white blood cell production by bone marrow. However, the ability of ponatinib hydrochloride to target isoforms of the BCR-ABL gene typically leading to resistance in other known tyrosine kinase inhibitors provides an alternate form of therapy not previously available.Ponatinib Hydrochloride 준비 용품 및 원자재
원자재
준비 용품
Ponatinib Hydrochloride 공급 업체
글로벌( 101)공급 업체
공급자 | 전화 | 이메일 | 국가 | 제품 수 | 이점 |
---|---|---|---|---|---|
ATK CHEMICAL COMPANY LIMITED | +undefined-21-51877795 |
ivan@atkchemical.com | China | 32480 | 60 |
career henan chemical co | +86-0371-86658258 |
sales@coreychem.com | China | 29919 | 58 |
TianYuan Pharmaceutical CO.,LTD | +86-755-23284190 13684996853 |
sales@tianpharm.com | CHINA | 304 | 58 |
Biochempartner | 0086-13720134139 |
candy@biochempartner.com | CHINA | 967 | 58 |
Shochem(Shanghai) Co.,Ltd | 86-21-50800795 |
info@shochem.com | CHINA | 288 | 58 |
BOC Sciences | +1-631-485-4226 |
inquiry@bocsci.com | United States | 19553 | 58 |
Beijing Yibai Biotechnology Co., Ltd | 0086-182-6772-3597 |
sales04@yibaibiotech.com | CHINA | 419 | 58 |
TargetMol Chemicals Inc. | +1-781-999-5354 +1-00000000000 |
marketing@targetmol.com | United States | 19892 | 58 |
Hubei Ipure Biology Co., Ltd | +8613367258412 |
ada@ipurechemical.com | China | 10326 | 58 |
ANHUI WITOP BIOTECH CO., LTD | +8615255079626 |
eric@witopchemical.com | China | 23396 | 58 |
Ponatinib Hydrochloride 관련 검색:
Nintedanib
Capmatinib
Safinamide mesylate
Tofacitinib citrate
PI-103
Abemaciclib
Cabozantinib
Enzalutamide
R428
N-(5-tert-Butylisoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-ylethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea
WZ4002
Regorafenib
AP26113
4-(4-Methylpiperazinomethyl)-3-(trifluoromethyl)aniline
MK-1775
Niraparib
Galeterone
Ponatinib